Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
Details : Stride's Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Truvada Tablets, 200 mg/300 mg, of Gilead Sciences.
Product Name : Truvada-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 15, 2021
Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : King's College London | London School of Hygiene & Tropical Medicine | Africa Health Research Institute | Wits Health Consortium | University College, London | Ministry of Health, Uganda | Desmond Tutu HIV Foundation | Assistance Publique – Hôpitaux de Pa
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tenofovir Disoproxil Fumarate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 15, 2023
Lead Product(s) : Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : King's College London | London School of Hygiene & Tropical Medicine | Africa Health Research Institute | Wits Health Consortium | University College, London | Ministry of Health, Uganda | Desmond Tutu HIV Foundation | Assistance Publique – Hôpitaux de Pa
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir Disoproxil Fumarate
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India
Details : Tenofovir Disoproxil Fumarate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 29, 2023
Lead Product(s) : Tenofovir Disoproxil Fumarate
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Doris Duke Foundation | Université Protestant au Congo | Abbott Laboratories | Albert Einstein College of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
The COMBAT HBV Feasibility Trial
Details : Tenofovir Disoproxil Fumarate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis B.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Doris Duke Foundation | Université Protestant au Congo | Abbott Laboratories | Albert Einstein College of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization and no ALT flares off-treatment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 25, 2022
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tenofovir Disoproxil Fumarate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis B, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 02, 2022
Lead Product(s) : Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JNJ-3989,Tenofovir Alafenamide,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
Details : JNJ-3989 is a sub-cutaneous, ribonucleic acid interference (RNAi) therapy candidate which is designed to silence all HBV gene products and intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside a...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 01, 2022
Lead Product(s) : JNJ-3989,Tenofovir Alafenamide,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data showed that ATI-2173 alone, or in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated among the cohorts, and ATI-2173 and TDF suppressed HBV DNA and induced declines in biomarkers of cccDNA activity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 30, 2022
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tenofovir Disoproxil Fumarate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis B, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2022
Lead Product(s) : Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tenofovir Disoproxil Fumarate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis B, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 16, 2022
Lead Product(s) : Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable